Share This Page
Drugs in ATC Class D10AX
✉ Email this page to a colleague
Drugs in ATC Class: D10AX - Other anti-acne preparations for topical use
| Tradename | Generic Name |
|---|---|
| AZELAIC ACID | azelaic acid |
| FINACEA | azelaic acid |
| AZELEX | azelaic acid |
| ACZONE | dapsone |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class D10AX “Other anti-acne preparations for topical use”
Executive summary
ATC D10AX is a heterogeneous, formulation-driven topical acne segment where patent risk is typically concentrated in (1) specific active ingredients outside the dominant retinoid/benzoyl-peroxide/sulfur classes, (2) branded multi-ingredient combinations, and (3) product-specific delivery and dosing patents rather than broad “acne” claims. Market dynamics are shaped by FDA labeling boundaries, dermatologist preference for tolerability and low-irritation profiles, payer pressure on branded pricing, and the rapid erosion of exclusivity via multiple reformulations at the edge of listed exclusivity and Orange Book barriers. Patent estates in D10AX are often thick on formulation and manufacturing process claims but narrower on method-of-treatment scope, which affects the likelihood of durable exclusivity after first Paragraph IV filings.
What patents protect ATC D10AX other anti-acne preparations for topical use?
Answer: Protection is usually product-scoped: formulation composition, microstructure/particle engineering, topical vehicle systems, specific concentration ranges, and methods for making or using the formulation. For multi-ingredient products, the patent estate often includes claims that recite the full combination plus a defined vehicle and release/delivery behavior.
Common protection themes in D10AX-type topical acne products
Featured snippet summary: Expect patents on the exact topical composition and manufacturing method, and less frequently broad “treat acne” method claims.
- Formulation and vehicle systems
- Claims tied to emulsions, gels, foams, solutions, or suspension systems with defined viscosity, surfactant package, thickener, solvent, and pH.
- Particle size and dispersibility limits for insoluble actives.
- Concentration and dosing windows
- Defined ranges for “active + co-active” concentrations that preserve stability and irritation profile.
- Release and penetration control
- Patents on controlled release matrices, lipophilic carriers, or polymer networks intended to alter skin penetration kinetics.
- Manufacturing process claims
- Stepwise process claims for mixing order, milling, sterilization/bioburden steps, filtration, packaging, and in-process controls.
- Method-of-use claims
- Often narrower and tied to specific dosing regimens (frequency, duration, wash-off vs leave-on, combination with other therapies, or maintenance use).
How to read a typical D10AX patent estate in litigation
Practical implication: If Orange Book listings exist, the “Orange Book blocking” strength usually concentrates in:
- compound/composition claims that map to the labeled formulation,
- one or two key formulation patents with broad claim construction, and
- manufacturing process claims that can block biosimilar-style “design-around” only if the generic must use the same process.
Which companies hold the strongest patent estates in topical acne “other” preparations?
Answer: The strongest estates track the biggest branded, differentiated topical acne products that sit in “other” classifications rather than classic retinoid/benzoyl peroxide. The key players are typically established dermatology companies plus topical-ingredient specialists, and the most frequent challengers are large generic firms that file Paragraph IV ANDAs and value portfolio cross-licensing.
Typical estate ownership patterns for D10AX-like categories
- Branded originators: Hold composition and process patents plus lifecycle patents for stability and improved skin tolerance.
- Licensees/co-developers: Often appear as assignees on formulation patents after partnering for manufacturing scale-up or region-specific submissions.
- Generic entrants: Rarely hold competing patents in the same delivery space unless they file their own formulation changes or process improvements.
When does exclusivity expire for branded “other anti-acne” topical acne products?
Answer: Exclusivity commonly ends in two steps:
- regulatory exclusivity tied to first approval and new clinical investigations, then
- patent exclusivity via Orange Book-listed patents with staggered expiration.
Exclusivity timeline structure used in D10AX launches
- 5-year NCE data exclusivity: if the active ingredient is new to the US.
- 3-year new clinical investigation exclusivity: if the label adds new efficacy/safety evidence.
- 6-month pediatric exclusivity: when granted on top of patent term or regulatory exclusivity.
- Oral/Topical exclusivity differences: Topicals often rely on composition and formulation patents rather than new MoAs, increasing the importance of Orange Book-listed formulation patents.
Why D10AX timing is often “patent-led,” not exclusivity-led
D10AX is fragmented, so multiple products reach market with different patent stagger. As a result, “first generic” dates are usually controlled by the Orange Book’s latest-expiring listed patent that is relevant to the ANDA product.
What is the Orange Book status of topical acne products in ATC D10AX?
Answer: D10AX products that have FDA-approved NDA routes with active Orange Book listings generally show one or more formulation patents plus at least one method-of-use or composition-of-matter claim. ANDA compatibility depends on whether the ANDA filer challenges the listed patents via Paragraph IV (or certifies them as non-infringing/invalid).
Orange Book listing patterns to expect in D10AX
- Multiple patents per NDC: often staggered across composition, formulation, and process.
- Method-of-use patents sometimes listed without broad coverage: can still block if claim construction is broad enough to read on the labeled regimen.
- Manufacturing process patents: frequently listed with limited generic design-around if the ANDA must match the same composition and release behavior.
How many patents cover “other” topical acne actives and combinations in D10AX?
Answer: The typical pattern is mid-single digits for each major branded product, with a concentration of claims in formulation and process patents. The number of enforceable patents varies by lifecycle strategy.
Patent count drivers
- Single active vs combination
- Combination products create multiplicative claim sets: full combination, sub-combinations, vehicle-specific combinations, and process variants.
- Multiple dosage forms
- If both gel and cream exist, expect parallel formulation patents by dosage form.
- Manufacturing transfers
- Scale-up and tech transfer often yield separate process and impurity-control patents.
What generic entry risks exist for D10AX topical acne products?
Answer: Generic risk is driven by (1) whether Orange Book has enforceable formulation patents with broad claim scope, (2) whether the ANDA can establish bioequivalence for topical exposure, and (3) whether the generic’s vehicle and process can design around without compromising stability, irritation profile, or performance measures.
Paragraph IV risk factors
- Claim breadth: composition patents with broad ranges can deter “close-enough” reformulation.
- Vehicle specificity: if claims require particular vehicle architecture, design-around is harder.
- Process determinism: process claims can force litigation over manufacturing details.
- Comparability of clinical endpoints: topical equivalents can face disputes beyond mere composition matching.
What patent litigation affects topical acne “other” products?
Answer: Litigation in D10AX-like topical acne typically targets formulation equivalence and manufacturing/process claims, with outcomes often determined at claim construction and whether the generic’s ANDA formulation reads on the asserted claims.
Typical litigation cycle for D10AX-type products
- ANDA submission with Paragraph IV certification.
- Notice of Paragraph IV triggers 30-month stay if not resolved earlier.
- Claim construction fights on:
- concentration ranges and stability-related parameters,
- vehicle composition elements,
- particle size/dispersibility criteria, and
- process steps tied to product quality attributes.
Settlement structures seen in topical acne
- Design-around licensing: generic can launch only with modified formulation constraints.
- Blended settlement date: delayed launch until an agreed patent expiration date with ongoing payments tied to exclusivity windows.
How do D10AX topical acne products compare with other ATC acne classes on patent durability?
Answer: Compared with retinoids (often with long-running compound/process estates) and benzoyl peroxide combinations (often more “commodity-like”), D10AX products tend to have more vehicle- and delivery-engineering patents, which can create localized durability but also frequent “generic workaround” attempts.
Patent durability comparison (high-level)
- Retinoids: often more durable due to broader compound families and long lifecycle.
- Benzoyl peroxide/sulfur staples: more crowded with older patents; durability often shorter.
- D10AX “other”: durability can be product-specific. A successful generic design-around can still face litigation if claims are broadly written around the vehicle or release profile.
What formulations are protected by patents in D10AX “other” anti-acne topical use?
Answer: The protected formulations are usually leave-on or wash-off topical compositions with specified vehicle systems, pH windows, and active distribution behavior.
Formulation archetypes commonly covered
- Gel/serum leave-on formulations
- Defined polymer thickeners, solvents, and penetration enhancers with specific active loadings.
- Cream/ointment emulsions
- Vehicle claims often hinge on emulsifier package, oil phase composition, and viscosity/texture.
- Foam/solution systems
- Propellant or solvent composition can generate separate process and stability claims.
- Multi-active formulations
- Patents often require the entire active package and vehicle; substitutes that drop one component often fall outside claim scope.
What method-of-use patents apply to topical acne “other” preparations?
Answer: Method-of-use patents are usually tied to treatment regimens that are more specific than “treat acne,” including dosing frequency, duration, and combination sequencing.
Typical method-of-use claim features
- Frequency constraints: once daily vs twice daily, ramp-up schedules, or “use at bedtime” requirements.
- Duration windows: initial lead-in phase plus maintenance.
- Combination sequencing: applying one active before another to reduce irritation.
- Population tailoring: claims sometimes specify subsets (e.g., moderate vs severe acne) and outcomes.
How does FDA regulatory status influence patent leverage in D10AX?
Answer: FDA labeling and Orange Book listings determine enforcement leverage; patent strength determines how much leverage the originator retains once ANDAs are filed. In D10AX, enforcement often concentrates on product-specific patents listed for the approved NDA.
Regulatory factors that shape litigation and launch timing
- NDC-by-NDC listing granularity
- Some patents list only certain strengths or dosage forms.
- Supplemental approvals
- Lifecycle changes can add new patents tied to reformulated versions, extending enforcement for those specific SKUs.
- Topical performance standards
- Even with composition equivalence, generic performance attributes can be litigated.
Which FDA pathways and filing strategies drive Paragraph IV in topical acne?
Answer: Generic firms typically use ANDA pathways for approved topical acne drugs. Paragraph IV strategies target the earliest-expiring or most easily asserted Orange Book patents, while retaining optionality to add other certifications later if litigation narrows claim coverage.
Strategy patterns seen across topical OTC-prescription adjacent markets
- First-to-file incentives: market capture if the originator’s estate is fragmented.
- Multiple ANDAs by strength/dosage form: to exploit gaps in Orange Book coverage.
- Settlement-driven design changes: licensing agreements that permit launch with altered vehicle/process parameters.
What is the competitive landscape for D10AX “other” topical acne preparations?
Answer: Competition is high on tolerability, cosmetically elegant vehicles, and differentiated actives or combinations. Patent barriers concentrate on the branded product’s precise formulation and manufacturing reproducibility.
Competitive drivers
- Dermatologist prescribing and patient adherence
- Smoother textures and fewer irritation events carry commercial weight independent of actives.
- Payer formularies
- Step edits and coverage tiers can shift uptake from branded to lower-cost equivalents even while patents remain active.
- Channel mix
- Prescription dermatology brands may compete with pharmacy chains and subscription retail for share.
Key Takeaways
- D10AX is a formulation and lifecycle-driven segment where patent estates often focus on topical vehicles, concentration windows, particle/delivery parameters, and manufacturing process.
- Exclusivity timing is typically controlled by Orange Book-listed patents tied to specific NDCs and dosage forms; regulatory exclusivity is usually the second layer.
- Generic entry risk is high when asserted formulation claims are narrow in vehicle architecture; it drops when claims define broad vehicle components or stability-linked parameters that are hard to replicate.
- Litigation in D10AX is commonly claim construction and formulation-readout oriented, with settlement and design-around licenses as frequent outcomes.
FAQs
1) What claim types most often block generic ANDAs for topical acne “other” products?
2) Do topical acne patents rely more on composition claims or method-of-use claims in D10AX?
3) How do supplemental NDA approvals change Orange Book exposure for branded D10AX products?
4) What does a design-around typically change in a topical acne formulation patent dispute?
5) How do pediatric exclusivity grants affect the effective launch date of generic topical acne products?
References
No sources were cited.
More… ↓
